Comparing two drug combos before stem cell transplant for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a new drug combination (Dec-FB4) works better than an existing one (FB4) as preparation for a stem cell transplant in people with acute myeloid leukemia that is in remission. The goal is to improve outcomes for patients who have a suitable donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 16 and 65 years old.
- You have acute myeloid leukemia that is in remission and has no detectable cancer cells (MRD negative).
- You have a stem cell donor who is a matched sibling, unrelated donor, or a half-matched family member.
- Your heart, liver, lungs, and kidneys are working well enough (based on standard tests).
- You are willing and able to follow the treatment plan and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (SHR2554 plus azacitidine) given before a stem cell transplant to treat aggressive leukemia, myelodysplastic syndrome, or lymphoblastic leukemia. The goal is to reduce cancer cells before transplant and improve outcomes.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a new combination of three chemotherapy drugs (clofarabine, busulfan, and melphalan) given before a stem cell transplant to treat acute myeloid leukemia (AML) in patients who have responded well to initial treatment. The goal is to improve how well the transplant works and how long patients survive.
This trial is testing two different chemotherapy regimens (with one or two alkylating agents) before a stem cell transplant for people with acute myeloid leukemia or myelodysplastic syndrome. The goal is to find which conditioning treatment is safer and more effective.
Hear when a new AML, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.